Acadia Pharmaceuticals

495 articles with Acadia Pharmaceuticals

• Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021

  7/21/2021

  Company to host conference call and webcast on Wednesday, August 4, 2021, at 4:30 p.m. Eastern Time

• Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)

  7/14/2021

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer’s Association International Conference ® 2021 (AAIC ® ), being held July 26-30, 2021 in Denver, Colo., and virtually.

• NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders

  6/3/2021

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced publication of open-label extension (OLE) data from patients experiencing hallucinations and delusions associated with Parkinson’s disease psychosis (PDP) who had previously completed one of three, six-week, double-blind, placebo-controlled studies.

• Acadia Pharmaceuticals to Present at Upcoming Investor Conferences - May 26, 2021

  5/26/2021

  Jefferies 2021 Virtual Healthcare Conference Fireside Chat Presentation: Wednesday, June 2, 2021 at 1:30 p.m. Eastern Time.

• Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results

  5/5/2021

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021.

• Acadia Pharmaceuticals to Present at Upcoming Investor Conferences - May 04, 2021

  5/4/2021

  BofA Securities 2021 Health Care Conference Fireside Chat Presentation: Wednesday, May 12, 2021 at 2:45 p.m. Eastern Time.

• Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021

  4/21/2021

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021, after the close of the U.S. financial markets

• Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

  4/5/2021

  Acadia Pharmaceuticals Inc. Conference call and webcast to be held today at 8:00 a.m. Eastern Time

• 

  Acadia's Nuplazid Receives Regulatory Rejection for Dementia-Related Psychosis

  4/5/2021

  The U.S. FDA issued a Complete Response Letter (CRL) over Acadia Pharmaceuticals’ supplemental New Drug Application (sNDA) for Nuplazid for hallucinations and delusions associated with dementia-related psychosis.
• 

  FDA Action Alert: Merck, Aveo and Acadia

  3/29/2021

  As this week’s FDA Action Alert emphasizes, not everything goes as planned with the U.S. FDA. With three PDUFA dates, two of them ran into issues. Read on to find out more.

• Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

  3/8/2021

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company received a notification from the U.S. Food and Drug Administration (FDA) on March 3, 2021, stating that, as part of its ongoing review of the Company’s supplemental New Drug Application (sNDA), the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.

• Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

  2/24/2021

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2020.

• Acadia Pharmaceuticals to Present at Upcoming Investor Conferences - Feb 18, 2021

  2/18/2021

  Acadia Pharmaceuticals Inc. announced that it will participate at the following investor conferences

• Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

  2/10/2021

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, after the close of the U.S. financial markets.

• Acadia Pharmaceuticals Announces Commercial Leadership Change

  1/27/2021

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Michael Yang, Executive Vice President and Chief Commercial Officer, will be leaving the organization effective January 29, 2021 to assume the role of chief executive officer at another healthcare company.

• Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021

  12/22/2020

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 2:00 p.m. Eastern Time, followed by a question and answer session.

• Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020

  11/10/2020

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 3:20 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia-pharm.com , under the investors section and an archived recording will be available on the website thr

• Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results

  11/4/2020

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2020. “This quarter we drove strong performance through the conti

• Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020

  10/21/2020

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 4, 2020, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on Wednesday, November 4, 2020, at 4:30 p.m. Eastern Time to

• The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”

  10/14/2020

  The Lewy Body Dementia Association and Acadia Pharmaceuticals Inc. announced an exclusive partnership on the production and release of a disease education adaptation of the new film Robin’s Wish©, a documentary detailing the late actor Robin Williams’ courageous battle with the neurodegenerative disorder, Lewy body dementia.